ArrayExpress Uploader04409NRnon-responderNRnon-responderNRnon-responderNRnon-responderRresponderNRnon-responderRresponderNRnon-responderRresponderNRnon-responderRresponderNRnon-responderNRnon-responderNRnon-responderNRnon-responderNRnon-responderRresponderNRnon-responderNRnon-responderRresponderRresponderRresponderNRnon-responderNRnon-responderNRnon-responderRresponderRresponderNRnon-responderRresponderRresponderRresponderRresponderNRnon-responderNRnon-responderNRnon-responderRresponderNRnon-responderNRnon-responderRresponderNRnon-responderNRnon-responderNRnon-responderRresponderNRnon-responderRresponderNRnon-responderNRnon-responderRresponderRresponderNRnon-responderNRnon-responderNRnon-responderNRnon-responderRresponderRresponderNRnon-responderNEnot evaluableNEnot evaluableNEnot evaluableNEnot evaluableNEnot evaluableNEnot evaluableNEnot evaluableNEnot evaluableNEnot evaluablearrayexpress_sid4Purpose: To evaluate the presence of a gene expression signature present before treatment as predictive of response to treatment with...23715562E-GEOD-35640/profile/8773/arrayexpressuploader265cancerlunglung cancermelanomametastatic melanomaDec.12, 2014Falseidentification-of-a-predictive-gene-signature-to-rE-GEOD-35640_A-AFFY-44Identification of a predictive gene signature to recMAGE A3 antigen-specific cancer immunotherapy in metastatic melanoma and non-small-cell lung cancerSep.19, 2014Purpose: To evaluate the presence of a gene expression signature present before treatment as predictive of response to treatment with MAGE‑A3 immunotherapeutic in metastatic melanoma patients and to validate its predictivity in adjuvant therapy of early-stage lung cancer. Patients were participants in two Phase II studies of the recombinant MAGE‑A3 antigen combined with immunological adjuvants. mRNA from tumor samples (biopsies) collected before MAGE-A3 immunotherapy was analyzed by microarray hybridization and by quantitative polymerase chain reaction (qRT-PCR). The melanoma microarray dataset was used to discover and crossvalidate a gene expression signature and classifier discriminative of Responders (R) versus Non-Responders (NR) patients; the gene signature and classifier were then applied to an adjuvant lung cancer study. Patients that were not included for analysis are denoted as NE (Non-evaluable). GSK Biologicalshttp://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-35640humanhttp://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-35640/samples/